Correlation Engine 2.0
Clear Search sequence regions

The reaction of the ruthenium(II) complex fac-[Ru(CO)(3)Cl(2)(N(1)-thz)] (I hereafter; thz = 1,3-thiazole) with human beta-amyloid peptide 1-28 (Abeta(28)) and the resulting {Ru(CO)(3)}(2+) peptide adduct was investigated by a variety of biophysical methods. (1)H NMR titrations highlighted a selective interaction of {Ru(CO)(3)}(2+) with Abeta(28) histidine residues; circular dichroism revealed the occurrence of a substantial conformational rearrangement of Abeta(28); electrospray ionization mass spectrometry (ESI-MS) suggested a prevalent 1:1 metal/peptide stoichiometry and disclosed the nature of peptide-bound metallic fragments. Notably, very similar ESI-MS results were obtained when I was reacted with Abeta(42). The implications of the above findings for a possible use of ruthenium compounds in Alzheimer's disease are discussed.


Daniela Valensin, Paolo Anzini, Elena Gaggelli, Nicola Gaggelli, Gabriella Tamasi, Renzo Cini, Chiara Gabbiani, Elena Michelucci, Luigi Messori, Henryk Kozlowski, Gianni Valensin. fac-{Ru(CO)(3)}(2+) selectively targets the histidine residues of the beta-amyloid peptide 1-28. Implications for new Alzheimer's disease treatments based on ruthenium complexes. Inorganic chemistry. 2010 Jun 7;49(11):4720-2

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 20459130

View Full Text